pornBLOCK

hidden_text

Online shopping for the latest electronics, fashion, phone accessories, computer electronics, toys, home&garden, home appliances, tools, home improvement and more.

Just last week the AstraZeneca Covid-19 jab received a top-level welcome in South Africa, but the country’s health minister now says it may sell or swap its stock, after a study questioned its efficacy against the local strain.

Speaking at a news conference on Wednesday, Health Minister Zweli Mkhize revealed the country was set to begin rolling out Johnson & Johnson’s vaccine next week.

The vaccination drive will come as an “implementation study” and will target the country’s health workers. So far, South Africa has secured only a small batch of the J&J vaccine, amounting to some nine million doses.

Depending on how the J&J solution fares against the local, extra-contagious strain of coronavirus, South Africa might sell or swap its stock of AstraZeneca vaccine, the minister suggested.

Why not sell the AstraZeneca to other countries, well it's an option ... we will consider it. First our scientists will tell us what we do with it, can we use it within the time that's available ... before it expires … If not, can we swap it with anyone else.

South Africa received its first million-dose batch of AstraZeneca jabs, manufactured by the Serum Institute of India (SII), last week. The haul received a warm welcome, with top officials including President Cyril Ramaphosa meeting it at an airport. The country is set to receive 500,000 additional doses of AstraZeneca in the weeks to come.

Also on rt.com
FILE PHOTO
South Africa SUSPENDS AstraZeneca vaccine rollout after study shows its ‘limited efficacy’ against local variant

The rollout of the AstraZeneca jab was suspended over the weekend, however, after a study by South Africa’s University of the Witwatersrand and Oxford University showed disappointing results regarding its efficacy. The study, which has not yet been peer-reviewed, suggested the jab offers significantly less protection against the South African extra-contagious variant of the virus, as well as against mild cases of the disease.

While the study has been already criticized by some experts over its limited scope, AstraZeneca acknowledged its results. Still, the pharmaceutical giant said it was too early to draw final conclusions about its jab, expressing hopes that it at least “should work” against severe cases of the disease.

Also on rt.com
Healthcare workers chat at a temporary ward set up at Steve Biko Academic Hospital in Pretoria, South Africa on January 19, 2021.
South Africa receives its first 1 million-dose batch of Covid-19 vaccine

South Africa has recorded the most Covid-19 infections and deaths on the African continent, with its tally nearing the 1.5 million mark. More than 45,000 people have succumbed to the disease across the country. Still, the nation’s first continental place in the coronavirus ranking might partially stem from poor testing rates among many other African nations.

Think your friends would be interested? Share this story!



from RT World News https://ift.tt/370mAlw

Just last week the AstraZeneca Covid-19 jab received a top-level welcome in South Africa, but the country’s health minister now says it may sell or swap its stock, after a study questioned its efficacy against the local strain.

Speaking at a news conference on Wednesday, Health Minister Zweli Mkhize revealed the country was set to begin rolling out Johnson & Johnson’s vaccine next week.

The vaccination drive will come as an “implementation study” and will target the country’s health workers. So far, South Africa has secured only a small batch of the J&J vaccine, amounting to some nine million doses.

Depending on how the J&J solution fares against the local, extra-contagious strain of coronavirus, South Africa might sell or swap its stock of AstraZeneca vaccine, the minister suggested.

Why not sell the AstraZeneca to other countries, well it's an option ... we will consider it. First our scientists will tell us what we do with it, can we use it within the time that's available ... before it expires … If not, can we swap it with anyone else.

South Africa received its first million-dose batch of AstraZeneca jabs, manufactured by the Serum Institute of India (SII), last week. The haul received a warm welcome, with top officials including President Cyril Ramaphosa meeting it at an airport. The country is set to receive 500,000 additional doses of AstraZeneca in the weeks to come.

Also on rt.com
FILE PHOTO
South Africa SUSPENDS AstraZeneca vaccine rollout after study shows its ‘limited efficacy’ against local variant

The rollout of the AstraZeneca jab was suspended over the weekend, however, after a study by South Africa’s University of the Witwatersrand and Oxford University showed disappointing results regarding its efficacy. The study, which has not yet been peer-reviewed, suggested the jab offers significantly less protection against the South African extra-contagious variant of the virus, as well as against mild cases of the disease.

While the study has been already criticized by some experts over its limited scope, AstraZeneca acknowledged its results. Still, the pharmaceutical giant said it was too early to draw final conclusions about its jab, expressing hopes that it at least “should work” against severe cases of the disease.

Also on rt.com
Healthcare workers chat at a temporary ward set up at Steve Biko Academic Hospital in Pretoria, South Africa on January 19, 2021.
South Africa receives its first 1 million-dose batch of Covid-19 vaccine

South Africa has recorded the most Covid-19 infections and deaths on the African continent, with its tally nearing the 1.5 million mark. More than 45,000 people have succumbed to the disease across the country. Still, the nation’s first continental place in the coronavirus ranking might partially stem from poor testing rates among many other African nations.

Think your friends would be interested? Share this story!

>